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It is not straightforward to simultaneously evaluate benefits and harms of pain 
management, as different drugs may possess different analgesia and adverse effect profiles. 
Utility functions, derived from the pharmacokinetics and pharmacodynamics of individual 
outcome parameters, have been constructed to address this problem. Here we construct 
‘pragmatic’ utility functions based on measurements of benefit and harms, but without 
making assumptions about the underlying pharmacokinetics and pharmacodynamics. Using 
data from two previous studies, utility functions were designed by estimating the probability 
of occurrence of benefit and harm and combining these into one function. Study 1 was a 
clinical trial on the effect of oral pregabalin on pain relief in chronic pancreatitis patients, 
with end-points analgesia and dizziness monitored for 21 days. Study 2 was an experimental 
study on the effect of intravenous fentanyl on antinociception and respiratory depression in 
healthy volunteers. From study 1 the utility function was negative the first week of 
treatment, indicative of the greater probability of dizziness than analgesia, but positive 
thereafter. From study 2 the utility function showed a nadir 30 minutes after dosing, after 
which the probability function slowly increased towards zero. A pragmatic utility function 
based on the probability of two binary outcomes, analgesia and adverse effect, was 
successfully constructed using data from two previous studies. Results yielded valuable 
insights into the utility of treatment and may be highly educative for physicians and may be 
used in development of potent analgesics with serious side effects.   
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Treatment of acute and chronic pain with opioid- and non-opioid medication comes with 
adverse effects that may cause harm and limit patient and doctor compliance (Dahan et al., 
2017b). Still, some adverse effects are considered acceptable, especially when these effects 
are relatively minor compared to the wanted effect (analgesia), others are potentially life-
threatening (e.g. respiratory depression). Additionally, adverse effects may vary over time 
with some increasing and others vanishing during the treatment period.  It is often not 
straightforward how to consider benefit and harm of treatment as they may have different 
concentration-effect relationships. The Leiden group recently developed so-called utility or 
safety functions to capture opioid toxicity (e.g. potentially lethal respiratory depression, 
sedation or dizziness) and benefit into one function (Boom et al., 2013; Dahan et al., 2015; 
Dahan et al., 2017a; Roozekrans et al., 2018; Yassen et al., 2008). These functions are based 
on the economic principle that the benefit of an action (i.e. treatment with one or more 
specific drugs) comes at the cost of a specific harm (i.e. adverse effects) (Sheiner and 
Melmon 1978). Such functions may be used early on in drug development, to compare drug 
utility among different patient populations, or to determine a dose regimen in specific 
patients ensuring more benefit than harm. In summary, these functions allow objective 
characterization of the opioids behavior at both ends of the spectrum. 
 
The Utility Functions (U) described by Boom et al. (2013) and Roozekrans et al. (2018) were 
based on population pharmacokinetic-pharmacodynamic models. This enables the 
quantification of the utility versus (effect-site) concentration, and to simulate and predict 
the utility at specific clinical settings other than those under which the pharmacokinetic (PK) 
and pharmacodynamic (PD) data were acquired. However, there may be studies where PK-
PD modeling is not part of the data analysis. For example, in the case drug plasma 
concentrations are not measured and consequently no pharmacokinetic model is available. 
For these situations, we propose to construct so-called ‘pragmatic’ utility functions that are 
based on measurements of benefit and harm but make no assumptions about the 
underlying PK and PD. In this study we developed these pragmatic utility functions based on 
data from two previous studies (Olesen et al., 2011; Boom et al., 2013).    
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Materials and Methods 
 
Study design 
The first study from which data were obtained to develop a pragmatic utility function is a 
study on the effect of oral pregabalin on pain relief in thirty-four chronic pancreatitis 
patients, in which analgesia and dizziness were monitored for 21 days (Olesen et al., 2011). 
The second study is on the effect of intravenous fentanyl on anticonception and respiratory 
depression in twelve healthy volunteers (Boom et al., 2013). Both studies were approved by 
the local institutional review boards and from all subjects written informed consent was 
obtained prior to participation in the trial.  
 
Study 1. Sixty-four patients with moderate to severe pain from chronic pancreatitis were 
randomized to receive increasing oral doses of the gabapentoid pregabalin or placebo for 3 
weeks. The initial pregabalin/placebo dose was 75 mg twice daily (bid); on day 3 the dose 
was increased to 150 mg bid and finally on day 7 to 300 mg bid. In case of unacceptable 
adverse effects, the dose could be adjusted to the previous dose (i.e. from 300 to 150 mg 
bid, or from 150 to 75 mg bid). For the construction of the utility functions, we used data of 
the 34 patients that received active medication: 21 men, 13 women, age 52 ± 10 years, 
duration of pancreatitis 8.5 ± 6.2 years. Maximum daily pain score was5.8 ± 2.3 units on an 
11-point numerical rating scale (NRS) from 0 (no pain) to 10 (most severe pain imaginable). 
Pain scores and adverse effects (including dizziness, score as a binary outcome) were 
obtained on days 0 (pre-treatment baseline), 4, 7, 11, 14, 17 and 21 of treatment.   
 
Study 2. Twelve healthy male volunteers (aged 18-25 years, body mass index 20-28 kg/m2) 
received a bolus fentanyl infusion of 3.5 µg/kg on two separate occasions. On the first study 
day, the influence of fentanyl on isohypercapnic ventilation was measured for 6 hours using 
the “dynamic end-tidal forcing” technique (see Dahan et al. (2007) for explanation of the 
technique). End-tidal PCO2 was clamped such that ventilation was 20 ± 2 L/min prior to 
fentanyl administration. On the second study day, the effect of fentanyl on pain tolerance to 
an electrical stimulus was measured for 6 hours. A noxious electrical stimulus train was 
applied using a custom-made computer-interfaced constant current stimulator. The current 
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was increased from 0 mA with 0.5 mA/s until the subject pressed a control button at pain 
tolerance, at which the stimulus train ended. 
 
Construction of the pragmatic utility function 
To construct utility functions, both harm (H) and benefit (B) were treated as binary 
outcomes: these occur or not. The probability 𝑝 that a binary outcome occurs is estimated 
by the proportion denoted by 𝜋. So, 𝜋 is calculated as the number of subjects where the 
outcome occurs divided by the number of subjects 𝑛. The variance of the proportion is given 
by var{p} = p × (1 – p)/n.     
 
In study 1, benefit was significant analgesia, and harm was dizziness. Significant analgesia 
was defined as a pain score that is lower than 50% of the baseline score (i.e. a pain score 
reduction > 50%). The proportion of subjects having significant analgesia at time 𝑡 is denoted 
by pB(t); the proportion of subjects experiencing dizziness is denoted by pH(t). Similarly, in 
study 2, B was significant antinociception (a 50% increase in electrical pain tolerance) and H 
significant respiratory depression (a 50% depression of ventilation). The proportion of 
subjects having significant antinociception at time 𝑡 is denoted by pB(t); the proportion of 
subjects experiencing significant respiratory depression is denoted by pH(t). From now on, 
we will use the term analgesia also for the antinociceptive responses observed in study 2.  
 
The classical definition of the utility function U , the probability of benefit minus the 
probability of harm, is given in this case by (Boom et al., 2013): 
U1 = pB - pH      eqn. 1 
The variance of U1 can be estimated by var{pB} + var{pH}, assuming the probabilities of 
benefit (analgesia) and harm (respiratory depression)  are independent. The definition of 
utility first used by Roozekrans et al. (2018) is the probability of analgesia without harm (e.g. 
dizziness or respiratory depression). Its estimate is also a proportion:  
U2 = pB and not H      eqn. 2 
so the number of subjects having analgesia without harm, divided by the number of 
subjects.  
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In Boom et al. (2013), it was recognized that the utility is dependent on the selected 
thresholds for benefit and harm. Therefore, in Roozekrans et al. (2018), we explored the 
impact of changing the threshold for analgesia and by doing so were able to create so-called 
"utility surfaces", where the thresholds for analgesia were depicted by different colors. First, 
the probability range of zero to one was divided into two ranges. The first range depicts the 
(estimated) probability of no harm with colors green to yellow, the second the probability of 
harm with colors orange to red. The changes in color were determined by the probability 
distribution functions, where these are functions of the threshold for analgesia. So, the 
empirical distribution is the proportion pB(t,q), where q denotes threshold. The thresholds 
are determined by the observed data. Depending on the levels of analgesia and harm, four 
extremes are defined: pain relief without harm (B+/H- denoted by the color green in 
Roozekrans et al., 2018), no pain relief and no harm (B-/H-, yellow), harm without pain relief 
(B-/H+, red) and finally harm with pain relief (B+/H+, orange). Gradients in between these 
extremes are depicted by corresponding colors depending on threshold 𝜃. The R code for 
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Study 1. Twenty-four patients (70%) showed improvement of pain scores during the 3-week 
pregabalin treatment. Dizziness occurred in 13 patients (38%); of all reported side effects 
dizziness occurred most frequently. The probability of analgesia (pB) and dizziness (pH) are 
given in Figure 1, panels A and B. The utility function U1 (eqn. 1, i.e. benefit – harm) is given 
in Figure 1C. The function is negative in the first week of treatment, indicative of the greater 
probability of adverse effect than analgesia, but positive thereafter. In Figure 2, the utility 
surface is given. The probability of experiencing neither benefit nor harm from pregabalin 
treatment (yellow surface) decreases over time from 40% at day 4 of treatment to 15% on 
day 21; the probability of just harm peaks at day 7 (20%) and is <10% at day 21. The 
probability of just benefit (green and green/yellow surface) slowly increases over time from 
40% at day 4 to 70% at day 21. However, when we apply the threshold of 50%, the 
probability of analgesia >50% was just 10% on day 4 and 45% on day 21 (deep green surface; 
see also Fig. 1D). The probability of benefit that coincides with harm was stable over time 
(approx. 10%; orange surface).  
 
Study 2. Antinociceptive responses and respiratory depression were observed in all 
participants, albeit with differences in magnitude and dynamics. The probability pB (increase 
in pain tolerance > 50%) was between 20 and 30% during the first 4 hours after fentanyl 
administration (Fig. 3A). The probability function pH (reduction in minute ventilation > 50%) 
declines from 0.75, just following fentanyl administration, to 0 at t = 5 h (Fig. 3B). U1 shows a 
nadir at t = 30 min (value -0.5), after which the probability function slowly increases towards 
zero (Fig. 3C). U2 (probability of just analgesia) cycles between 0 and 0.2 (Fig. 3D). The utility 
surface (Fig. 4) show an initial high probability of harm without or with some analgesia 
(probability > 70%; red and orange surfaces), which slowly declines toward 10% at t = 4 h. 
The probability of just analgesia was low throughout the study period (< 10%). The 
remaining surface (yellow) indicates neither analgesia nor respiratory depression and 
increases from 20% at t = 5 min to 100% at the end of the study, an indication that fentanyl 
concentrations at the effect-site were low. 
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The desired effects of analgesics often coincide with a myriad of side effects that limit their 
usefulness in clinical practice due to reduced patient compliance and possibly actual bodily 
harm. Particularly, with increasing doses the probability of adverse effects increases. For 
example, at high dose, opioid analgesics produce respiratory depression that may at one-
point cause instability of the ventilatory control system with repeated apneic events and/or 
upper airway obstruction (Dahan et al., 2017b). To improve our understanding of the 
analgesic’s utility, it is important to capture the different behaviors of drugs into a single 
function. Such a function may be used to assess the utility of a drug in specific patient 
populations, determine the optimum dose regimen (e.g. the lowest-effective dose that 
coincides with still acceptable side effects), and allow comparison among drugs. Evidently, 
the time domain also needs to be considered as some effects and side effects vary over time 
as drug mechanisms are activated. The drug (or drug dose) with the highest utility U2 (i.e. a 
drug with little pH and high pB) is then the best choice. Although desired and undesired drug 
effects may be initiated at a single receptor system, signal transduction pathways may differ 
with consequently non-parallel concentration-response relationships. Hence, simply basing 
the drug’s utility on the therapeutic index (the ratio of concentrations causing toxic vs. 
therapeutic effects) is difficult as the ratio is dose-dependent (Kharasch and Rosow, 2013).  
 
The concept of the utility function 
In recent years multiple often complex models have been constructed to study the 
combined desired and undesired effect of drug treatment. For example, the well-being 
model combines positive and negative effects of anesthetic drug combinations (Zanderigo et 
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al., 2006). We previously developed utility (or safety) functions based on the integrated 
positive and negative behavior of drug using a PK-PD modeling approach (Boom et al, 2013; 
Dahan et al., 2017; Roozekrans et al., 2018; Yassen et al., 2008). As implied by Henthorn and 
Mikulich-Gilberston (2018), these utility functions are not a formula or equation but rather 
an algorithm that gives a string of values (i.e. a function in 2 or 3 dimensions) that accounts 
for both desired and undesired outcomes. In the case of our examples in studies 1 and 2, we 
created functions that give an objective calculation of the probabilities of analgesia with and 
without significant dizziness or respiratory depression (with value q determining the 
threshold between non-significant and significant effects).  
 
Our utility function is based on the economic principle that the benefit of an action comes at 
the cost of a specific harm, i.e. U = benefit – harm. This concept has previously been applied 
in medicine for determination of the utility of antihypertensive therapy by Sheiner and 
Melmon (1978) and anticoagulant therapy by Cullberg et al. (2005). To construct the utility 
function, we previously performed population PK-PD modeling studies (Boom et al., 2013; 
Yassen et al., 2008). These are complex studies that require the availability of 
pharmacokinetic data and modeling capabilities. Here we propose a more pragmatic utility 
function based on the probabilities of benefit and harm.  
 
Pregabalin and fentanyl 
The results of our two examples are promising and the 3-dimensional response surfaces 
(Figs. 2 and 4) give a clear indication of the utility of pregabalin and fentanyl in their 
respective study populations, middle-aged chronic pancreatitis patients and healthy young 
volunteers, respectively. Dizziness is an important side effect of pregabalin therapy and 
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especially in elderly patients may result in falls and fractures. We show that dizziness 
without analgesia has a probability of approximately 20% occurring throughout the three-
week treatment period with oral pregabalin. Significant analgesia without dizziness 
increased over time from 5 to 25%. On average fifty percent of patients will experience 
either no or limited analgesic effects (yellow and yellow/green surfaces, Fig. 2) or have 
analgesia with dizziness (orange surface). We conclude from the utility surface analysis that 
utility of pregabalin treatment increases over time and, as such, the patient should be kept 
on pregabalin treatment for an appropriate time period (2-3 weeks) to allow an accurate 
assessment of benefit vs harm (utility). Nonetheless, our results indicate that pregabalin is of 
limited efficacy in chronic pancreatitis patients when the aim of therapy is significant pain 
relief, i.e. more than 50% reduction of baseline pain. Accepting less pain reduction increases 
the utility of the drug to 50-70% of patients, however, these effects coincided in a large 
proportion of patients with dizziness. On the other hand, reduction in pain intensity is only 
one aspect of the complex process of pain perception and different endpoints may show 
different results as demonstrated in the original report where significantly more patients in 
the pregabalin treated group rated their overall health situation as improved compared to 
the placebo treated group (Olesen et al., 2011). This indicates that B may be redefined, for 
example by using satisfaction with pain relief. Still even then benefit and harm would 
coincide in the majority of patients.  
 
Similarly, respiratory depression from opioids is important as well since it is potentially 
lethal, as is exemplified by the current opioid epidemic and large number of opioid deaths in 
the US (Okie, 2010; Anonymous, 2018). In study 2, we tested the effect of intravenous 
fentanyl in opioid-naive healthy volunteers. As expected from the relatively high dose (3.5 
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µg/kg), the probability of fentanyl-induced respiratory depression without much or any 
analgesia occurs immediately following injection and dissipates slowly. Analgesia did occur 
but was invariably coupled to respiratory depression. This indicates that it is difficult to 
induce significant fentanyl analgesia without respiratory depression in this population. 
Further studies are needed to assess the utility function of potent opioids in chronic pain 
patients as, so far, studies were limited to healthy volunteers and acute pain. Still, animal 
studies demonstrate that tolerance to opioid-induced respiratory depression may not occur 
when tolerance to analgesia has developed (Emery et al., 2016). We made similar 
observations in individuals that chronically use high-dose opioids (Albert Dahan, unpublished 
observation).   
 
Utility of the utility function 
The use of the pragmatic utility function has one important drawback. Constructing utility 
functions that are not based on PKPD models leads to inability to determine the utility as 
function of concentration. Consequently, the effects of alternative dose administration 
regimens cannot be assessed. In Study 1, for both functions U1 and U2, the highest utility was 
reached at 21 days of therapy (Fig. 1B and C). U1 is initially negative (but not different from 
zero), while U2 is invariably positive. When U1 = 0, we can only state that the probabilities of 
significant analgesia and dizziness are equal, i.e. pB = pH. If these probabilities are 
independent, U2 has a maximum probability of 0.25 at pB = pH = 0.5 since U2 = pB and not H = pb × 
pnot H = pB × (1 – pH). This indicates that of the two functions U1 and U2, U2 is the more 
informative about the actual drug utility. Finally, it is important to realize that utility 
functions U1 and U2 are context sensitive, i.e. they depend on the predefined threshold 
value, such as the threshold for significant analgesia). The utility surfaces (Figs. 2 and 4) give 
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an even more complete picture as they incorporate multiple thresholds with information on 
all four possible outcomes that range from the most desired condition B+/H- via B+/H+ and 
B-/H- to the least desired condition B+/H-. On the other hand, utility surfaces are more 
complex, and if the functions are to be used in clinical practise U1 is the most intuitive 
(Dahan et al, 2015). 
 
Comparison between model-based and pragmatic utility surfaces 
Since the pragmatic and model-based (or classic) utility surfaces are based on different 
analytical approaches, we compared the two utility surfaces derived from Study 2 (Fig. 4). 
First, we reconstructed the classic utility surface based on the measurement times (similar to 
the pragmatic utility function) (Fig. 4B) and next calculated the difference in probabilities per 
time unit for the eleven squares per time unit (each represent a probability quantile). The 
residuals are given in Figure 4C with deeper levels of blue indicative of larger residuals. Since 
the residuals are relatively small (on average < 0.1) and the larger residuals equally spread 
over the surface, we conclude that the two methods are comparable. Differences between 
the pragmatic and model-based utility functions are most likely caused by the fact that the 
model-based utility function by definition does not contain residual intra-individual error. 
The pragmatic utility is therefore more uncertain, and confounded by measurement error at 
baseline, which is the reference for determining benefit and harm; baselines are estimable 
parameters with the model-based approach. Still, the pragmatic utility function is sufficiently 
robust to be used as a potentially standalone option for the analysis of drug effects.  
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We successfully constructed pragmatic utility functions based on the probability of two 
binary outcomes, significant analgesia and adverse effect. We foresee an important role of 
these functions in model-based development of analgesics with less severe adverse effects 
relative to their benefit than current frequently used opioids (van der Schrier et al., 2017).  
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Legends to the figures 
 
Figure 1. Utility functions of Study 1. A. Probability of pregabalin-induced analgesia (benefit, 
pB). B. Probability of pregabalin-induced dizziness (harm, pH).  C. Utility function U1 = pB – pH 
or probability of benefit minus probability of harm. D. Utility function U2 = pB not H or the 
probability of benefit without any harm. Data are ± SD. 
 
Figure 2. Pragmatic utility surface of Study 1. Depending on the levels of analgesia and 
dizziness, four extremes are defined: pain relief without dizziness denoted by the color 
green, no pain relief and no dizziness (yellow), dizziness without pain relief (red) and 
dizziness with pain relief (orange). Gradients in between these extremes are depicted by 
corresponding colors.   
 
Figure 3. Utility functions of Study 2. A. Probability of fentanyl-induced antinociception 
(benefit, pB). B. Probability of fentanyl-induced respiratory depression (harm, pH).  C. Utility 
function U1 = pB – pH or probability of benefit minus probability of harm. D. Utility function 
U2 = pB not H  or the probability of benefit without any harm. Data are ± SD. 
 
Figure 4. Pragmatic (A) and classic (B) utility surfaces of Study 2. Depending on the levels of 
analgesia and respiratory depression, four extremes are defined: pain relief without 
respiratory depression denoted by the color green, no pain relief and no respiratory 
depression (yellow), respiratory depression without pain relief (red) and respiratory 
depression with pain relief (orange). Gradients in between these extremes are depicted by 
corresponding colors. C. Residuals of the difference of the pragmatic and classic utility 
surfaces of Study 2. The residuals range from 0 (light blue) to 1 (black).   
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